(Q36868686)

English

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden

scientific article published on May 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

0 references

polycythemia vera

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Ola Landgren

1 reference

Europe PubMed Central

16 August 2017

PMC publication ID

Sigurdur Y Kristinsson

3

object named as

Sigurdur Y Kristinsson

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Lynn R Goldin

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Elin A Helgadottir

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jan Samuelsson

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Magnus Björkholm

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

1 May 2008

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

112

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

2199-2204

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Biology and treatment of primary myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Oncogenes in myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Lessons from familial myeloproliferative disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Management of patients with polycythaemia vera: results of a survey among Swedish haematologists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

A long-term retrospective study of young women with essential thrombocythemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Diagnosis and classification of the polycythemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

29 September 2017

Estimating effects of probands' characteristics on familial risk: I. Adjustment for censoring and correlated ages at onset

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

27 June 2018

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

4 September 2018

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

4 September 2018

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2532797

4 September 2018

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera

1 reference

https://pubmed.ncbi.nlm.nih.gov/18451307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-03-143602

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36868686&oldid=2087904136"